AI assistant
ABBOTT LABORATORIES — Director's Dealing 2024
May 1, 2024
29777_dirs_2024-04-30_a4d1811c-8a83-4d4c-a222-efa6d13eddb0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2024-04-26
Reporting Person: STARKS DANIEL J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-26 | Common shares without par value | A | 1866 | — | Acquired | 6727182 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-26 | Option (right to buy) | $107.14 | A | 5277 | Acquired | 2034-04-25 | Common Shares (5277) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common shares without par value | 258 | Indirect |
Footnotes
F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F3: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.